Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TP-271
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2018
Lead Product(s) : TP-271
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TP-271
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Safety and PK Study of IV TP-271
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2017
Lead Product(s) : TP-271
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TP-271
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 TP-271 Oral PK Single Ascending Dose Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2017
Lead Product(s) : TP-271
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TP-271
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2016
Lead Product(s) : TP-271
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable